Pharmaceutical Networking: High-performance Bioprocessing Products
enGenes Biotech has created a portfolio of high-performance products to transform bioprocessing — from upstream fermentation to downstream purification.
The portfolio includes a cost-effective endonuclease and a versatile range of affinity ligands, all produced using the proprietary enGenes-eXpress™, -eXtra™, and -eXcite™ platforms to deliver reliability, scalability, and efficiency.
-eXrase™, ™ for smart DNA digestion, Real Cost Savings
-eXrase™, is a next-generation recombinant endonuclease that delivers powerful DNA/RNA digestion at a fraction of the cost of traditional market enzymes – without compromising performance.
It can be applied to control viscosity during cell harvest and clarification, to enhance filtration and purification throughput, and to increase recovery and purity of target proteins. This NextGen endonuclease is available in research-grade, technical-grade, and bulk formats.
-eXrase™ delivers tangible manufacturing efficiency benefits, including:
- Up to 30 times greater cost savings compared with nucleases such as Benzonase®
- Rapid reduction of lysate viscosity, enabling smoother downstream handling
- Improved chromatographic flow rates and higher protein yields
- Consistent, scalable production from -eXpress™ and -eXtra™ manufacturing
High-performance capture affinity ligands
enGenes has also developed a new family of high-performance affinity ligands that are designed to support efficient and selective purification of biotherapeutics, from discovery to large-scale manufacturing — without the price tag of traditional solutions.
Affinity ligands are molecules that can bind with high affinity to specific targets, such as Protein A, which has an extremely high affinity for some immunoglobulin molecules. Their use in Affinity chromatography has transformed the detection, purification, or modulation of biological activities.
The harnessing of natural molecule binding another through receptor–ligand interactions has also revolutionized manufacturing of large complex medicines based on monoclonal antibodies (mAbs).
The range of enGenes ligand products includes:
- Wild-Type Protein A
- Protein A with C-terminal Cysteine (for site-specific, directional immobilization)
- Synthetic Tetrameric and Hexameric Ligands
- Custom Ligands tailored to specific targets or processes
Again, these new ligands are manufactured using -eXpress™ and -eXtra™, with optional -eXcite™ enhancements for full end-to-end continuous production, with efficiencies that reduce the price and make them more accessible than ever before.
Other benefits include:
- Optimized for high-efficiency capture of antibodies and proteins
- Exceptional binding stability and low leaching risk
- Enable site-specific, directional immobilization for enhanced process control
- Support cost-effective custom resin development using alternative Protein A sources — unlocking more affordable, tailored bioprocessing solutions